Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 500 of 517 entries
View as:

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04446260 Org: User:
Start: 09/07/20 End: 03/31/26 Due: 03/31/27

Comparison of HR011408 and NovoRapid® in Subjects With Diabetics

Phase: N/A Priority: Normal
NCT ID: NCT06375031 Org: User:
Start: 05/31/24 End: 07/15/24 Due: 07/15/25

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Phase: N/A Priority: Normal
NCT ID: NCT06099990 Org: User:
Start: 10/31/23 End: 12/31/28 Due: 12/31/29

A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02575651 Org: User:
Start: 04/30/15 End: 06/30/18 Due: 06/30/19

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06122389 Org: User:
Start: 02/05/24 End: 07/31/26 Due: 07/31/27

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04342936 Org: User:
Start: 07/17/20 End: 12/01/23 Due: 12/01/24

The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject

Phase: N/A Priority: Normal
NCT ID: NCT05737576 Org: User:
Start: 03/20/23 End: 12/08/23 Due: 12/08/24

The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis.

Phase: N/A Priority: Normal
NCT ID: NCT04417972 Org: User:
Start: 07/30/20 End: 05/14/24 Due: 05/14/25

Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01984489 Org: User:
Start: 06/30/12 End: 08/31/13 Due: 08/31/14

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT04333771 Org: User:
Start: 07/31/20 End: 09/21/23 Due: 09/21/24

Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05370950 Org: User:
Start: 05/25/22 End: 12/31/22 Due: 12/31/23

A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05560360 Org: User:
Start: 11/04/22 End: 01/27/23 Due: 01/27/24

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05320692 Org: User:
Start: 08/09/22 End: 07/30/26 Due: 07/30/27

A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05103826 Org: User:
Start: 10/25/21 End: 06/15/23 Due: 06/15/24

A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04842630 Org: User:
Start: 04/08/21 End: 11/01/22 Due: 11/01/23

Effect of Fluconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04850651 Org: User:
Start: 04/16/21 End: 05/17/21 Due: 05/17/22

A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03509636 Org: User:
Start: 04/04/18 End: 07/23/20 Due: 07/23/21

A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03904823 Org: User:
Start: 04/25/19 End: 12/31/22 Due: 12/31/23

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04869488 Org: User:
Start: 07/19/21 End: 02/14/23 Due: 02/14/24

Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04464733 Org: User:
Start: 07/20/20 End: 05/30/23 Due: 05/30/24

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04802811 Org: User:
Start: 03/22/21 End: 11/10/21 Due: 11/10/22

Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04839016 Org: User:
Start: 04/25/21 End: 08/30/23 Due: 08/30/24

The DDI Study of SP2086 and Simvastatin

Phase: N/A Priority: Normal
NCT ID: NCT02817243 Org: User:
Start: 03/31/16 End: - Due: -

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Phase: N/A Priority: Normal
NCT ID: NCT05533463 Org: User:
Start: 09/15/22 End: 12/30/24 Due: 12/30/25

A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT06035393 Org: User:
Start: 01/15/24 End: 08/28/25 Due: 08/28/26